Modernizing eligibility criteria for molecularly driven trials

Journal of Clinical Oncology

Volumn 33, Issue 25, 2015, Pages 2815-2820

  Kim, Edward S ^a   Bernstein, David ^b   Hilsenbeck, Susan G ^c   Chung, Christine H ^e   Dicker, Adam P ^g   Ersek, Jennifer L ^a   Stein, Steven ^h   Khuri, Fadlo R ⁱ   Burgess, Earle ^a   Hunt, Kelly ^d   Ivy, Percy ^f   Bruinooge, Suanna S ^b   Meropol, Neal ^j   Schilsky, Richard L ^b  

^a LEVINE CANCER INSTITUTE   (United States)

^b AMERICAN SOCIETY OF CLINICAL ONCOLOGY   (United States)

^c BAYLOR COLLEGE OF MEDICINE   (United States)

^d UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^e JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f NATIONAL CANCER INSTITUTE   (United States)

^g THOMAS JEFFERSON UNIVERSITY   (United States)

^h NOVARTIS PHARMA AG   (Switzerland)

ⁱ EMORY UNIVERSITY   (United States)

^j UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2B INTERFERON; AROMATASE INHIBITOR; BEVACIZUMAB; BUPARLISIB; CARBOPLATIN; CARFILZOMIB; CELECOXIB; CETUXIMAB; CISPLATIN; CYCLOPHOSPHAMIDE; CYTOTOXIC AGENT; DOCETAXEL; DOXORUBICIN; EMIBETUZUMAB; ERLOTINIB; EVEROLIMUS; FILANESIB; FLUOROURACIL; FOLINIC ACID; FULVESTRANT; GEMCITABINE; IMATINIB; IPILIMUMAB; OSIMERTINIB; PACLITAXEL; PANITUMUMAB; PROTEIN TYROSINE KINASE INHIBITOR; TRASTUZUMAB; UNINDEXED DRUG; VEMURAFENIB; ANTINEOPLASTIC AGENT; TUMOR MARKER;

ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER RESEARCH; CLINICAL EVALUATION; CLINICAL PROTOCOL; CLINICAL TRIAL (TOPIC); DRUG EFFICACY; DRUG SAFETY; HEALTH CARE ORGANIZATION; HEALTH CARE PERSONNEL; HEALTH CARE SYSTEM; HUMAN; MOLECULAR THERAPY; MOLECULARLY TARGETED THERAPY; MULTICENTER STUDY (TOPIC); MULTIMODALITY CANCER THERAPY; MULTIPLE MYELOMA; NON SMALL CELL LUNG CANCER; ONCOLOGY; PANCREAS ADENOCARCINOMA; PATIENT SAFETY; PHYSICIAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK BENEFIT ANALYSIS; WORKSHOP; ALGORITHM; GENETICS; METABOLISM; NEOPLASMS; PATIENT SELECTION; PROCEDURES; STANDARDS; TREATMENT OUTCOME; TRENDS;

ALGORITHMS; ANTINEOPLASTIC AGENTS; BIOMARKERS, TUMOR; CLINICAL TRIALS AS TOPIC; HUMANS; MEDICAL ONCOLOGY; MOLECULAR TARGETED THERAPY; NEOPLASMS; PATIENT SELECTION; TREATMENT OUTCOME;

EID: 84941370336     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2015.62.1854     Document Type: Article

References (26)

1. Tang JY, Mackay-Wiggan JM, Aszterbaum M., et al: Inhibiting the hedgehog pathway in patients with the basal-cell nevus syndrome. N Engl J Med 366:2180-2188, 2012
2. Ciardiello F, Tortora G: EGFR antagonists in cancer treatment. N Engl J Med 358:1160-1174, 2008
3. Shaw AT, Kim DW, Nakagawa K, et al: Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med 368:2385-2394, 2013
4. Pegram MD, Lipton A, Hayes D.F., et al: Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment. J Clin Oncol 16:2659-2671, 1998
5. Flaherty KT, Puzanov I, Kim K.B., et al: Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med 363:809-819, 2010
6. Druker BJ, Talpaz M, Resta D.J., et al: Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 344:1031-1037, 2001
7. US Food and Drug Administration: FDA approves Zykadia for late-stage lung cancer. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm395299.htm
8. US Food and Drug Administration: FDA approves Keytruda for advanced melanoma. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm412802.htm
9. George SL: Reducing patient eligibility criteria in cancer clinical trials. J Clin Oncol 14:1364-1370, 1996
10. Sateren WB, Trimble EL, Abrams J, et al: How sociodemographics, presence of oncology specialists, and hospital cancer programs affect accrual to cancer treatment trials. J Clin Oncol 20:2109-2117, 2002
11. Christian MC, Trimble EL: Increasing participation of physicians and patients from underrepresented racial and ethnic groups in National Cancer Institute-sponsored clinical trials. Cancer Epidemiol Biomarkers Prev 12:277s-283s, 2003
12. Lara PN Jr., Higdon R, Lim N., et al: Prospective evaluation of cancer clinical trial accrual patterns: Identifying potential barriers to enrollment. J Clin Oncol 19:1728-1733, 2001
13. West L, Vidwans SJ, Campbell N.P., et al: A novel classification of lung cancer into molecular subtypes. PLoS One 7:e31906, 2012
14. My Cancer Genome: Molecular profiling of lung cancer. http://www.mycancergenome.org/content/disease/lung-cancer/
15. Fehrenbacher L, Ackerson L, Somkin C: Randomized clinical trial eligibility rates for chemotherapy (CT) and antiangiogenic therapy (AAT) in a population-based cohort of newly diagnosed non-small cell lung cancer (NSCLC) patients. J Clin Oncol 27:332s, 2009 (suppl; abstr 6538)
16. Meropol NJ, Kris MG, Winer EP: The American Society of Clinical Oncology's blueprint for transforming clinical and translational cancer research. J Clin Oncol 30:690-691, 2012
17. US Food and Drug Administration: Frequently asked questions: Breakthrough therapies. http://www.fda.gov/RegulatoryInformation/Legislation/FederalFoodDrugandCosmeticActFDCAct/SignificantAmendmentstotheFDCAct/FDASIA/ucm341027.htm
18. US Food and Drug Administration: Guidance for industry: e16 biomarkers related to drug or biotechnology product development-Context, structure, and format of qualification submissions. http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm267449.pdf
19. Kim ES, Hirsh V, Mok T., et al: Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): A randomised phase III trial. Lancet 372:1809-1818, 2008
20. Sequist LV, Yang JC, Yamamoto N, et al: Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J Clin Oncol 31: 3327-3334, 2013
21. Hanna N, Shepherd FA, Fossella F.V., et al: Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol 22:1589-1597, 2004
22. Hauschild A, Grob JJ, Demidov L.V., et al: Dabrafenib in BRAF-mutated metastatic melanoma: A multicentre, open-label, phase 3 randomised controlled trial. Lancet 380:358-365, 2012
23. Korpanty GJ, Graham DM, Vincent M.D., et al: Biomarkers that currently affect clinical practice in lung cancer: EGFR, ALK, MET, ROS-1, and KRAS. Front Oncol 4:204, 2014
24. Somkin CP, Gross R, Liu H., et al: Automated data base screening of a population-based cohort of stage 1 colon cancer patients for eligibility in NSABP P-3, a polyp prevention study with celecoxib at Kaiser Permanente Northern California (KPNC). J Clin Oncol 24:54s, 2006 (suppl; abstr 1021)
25. Clement-Duchne C., Carnin C, Martinet Y: Too restrictive exclusion criteria in advanced stage lung cancer therapeutic trials: Are we missing the target? J Thorac Oncol 3:943, 2008
26. Somer RA, Sherman E, Langer CJ: Restrictive eligibility limits access to newer therapies in non-small-cell lung cancer: The implications of Eastern Cooperative Oncology Group 4599. Clin Lung Cancer 9:102-105, 2008.